# Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior

> **NCT01588951** · PHASE2,PHASE3 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 10 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine consolidation
- **DRUG:** Allogeneic transplant

## Key facts

- **NCT ID:** NCT01588951
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01588951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01588951, "Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01588951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*